Catch up on today's top five analyst upgrades with this list compiled by The Fly: Amgen (AMGN) upgraded to Buy from Neutral at BofA/Merrill with analyst Ying Huang saying he expects 14% earnings growth in 2017, compared to consensus of 8% and 8% for major pharma peers. Like consensus, Huang expects a downward trend for Epogen, but said the recent Davita (DVA) contract should result in a more gradual decline and the delay in Neulasta biosimilar launch will also help stabilize Amgen's revenue. Additionally, the analyst expects a positive outcome for the highly anticipated Repatha's cardiovascular outcome trial, new product launches in 2017, and potential benefits from cash repatriation. 2. Coach (COH) upgraded to Buy from Hold at Evercore ISI with analyst Omar Saad saying there are increasing signs that Coach is being successful in translating its full-price store formula to its lagging outlet business as it has undergone an ambitious brand turnaround over the past few years. 3. Leggett & Platt (LEG) upgraded to Strong Buy from Market Perform at Raymond James with analyst Budd Bugatch changing his view following the fourth quarter report and conference call saying he expects new bedding introductions to gain traction with a variety of mattress makers, spurring incremental 2017 growth, its vertical integration and market share position provide pricing power, and shares have declined 9% from its peak over the last six months. 4. Danaher (DHR) upgraded to Outperform from Neutral at Credit Suisse with analyst Erin Wilson Wright assuming coverage of the stock on enthusiasm for its growing exposure to compelling recurring revenues streams, healthy innovation pipeline, significant room for margin improvement, and capital deployment optionality. The analyst also raised her price target on the shares to $93 from $80. 5. Constellation Brands (STZ) upgraded to Hold from Reduce at HSBC with analyst Carlos Laboy citing the stock's 15% correction since the three-month high. The analyst views the stock as fairly valued and raised his price target for the shares to $153 from $132. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Baird raised the firm's price target on Danaher to $271 from $259 and keeps an Outperform rating on the shares. The firm said they reported 1Q results above expectations, helped by respiratory testing and bioprocessing upside. The company saw encouraging bioprocessing trends, with orders growing mid-single-digits, and noted normalization of large customer ordering patterns, with management expecting destocking to be largely complete by 2Q24-end.

Barclays raised the firm's price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company's orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.

Notable gainers among liquid option names this morning include Globe Life (GL) $71.33 +4.94, Super Micro (SMCI) $764.85 +47.83, Danaher (DHR) $250.88 +14.79, Kimberly Clark (KMB) $136.87 +7.94, and General Motors (GM) $45.38 +2.17.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here